Have a feature idea you'd love to see implemented?
Let us know!
LUMO Lumos Pharma Inc
Price (delayed)
$4.33
Market cap
$37.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.29
Enterprise value
$24.1M
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management
Highlights
The debt has dropped by 62% since the previous quarter and by 36% year-on-year
The revenue has grown by 48% from the previous quarter and by 27% YoY
LUMO's EPS is down by 7% year-on-year but it is up by 3.2% since the previous quarter
LUMO's net income is down by 6% YoY but it is up by 2.3% from the previous quarter
The equity has plunged by 86% YoY and by 52% from the previous quarter
LUMO's quick ratio has dropped by 70% year-on-year and by 39% since the previous quarter
Key stats
What are the main financial stats of LUMO
Market
Valuations
Earnings
Shares outstanding
8.65M
Market cap
$37.45M
Enterprise value
$24.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.16
Price to sales (P/S)
16.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.93
Revenue
$2.21M
EBIT
-$34.92M
EBITDA
-$34.9M
Free cash flow
-$31.67M
Per share
Balance sheet
Liquidity
EPS
-$4.29
Free cash flow per share
-$3.8
Book value per share
$0.6
Revenue per share
$0.26
TBVPS
$2.1
Total assets
$17.46M
Total liabilities
$12.55M
Debt
$172,000
Equity
$4.91M
Working capital
$10.77M
Debt to equity
0.04
Current ratio
2.66
Quick ratio
2.1
Net debt/EBITDA
0.38
Margins
Efficiency
Dividend
EBITDA margin
-1,582.5%
Gross margin
100%
Net margin
-1,583.5%
Operating margin
-1,647.6%
Return on assets
-129.9%
Return on equity
-233%
Return on invested capital
N/A
Return on capital employed
-318.7%
Return on sales
-1,583.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUMO stock price
How has the Lumos Pharma stock price performed over time
Intraday
0.23%
1 week
0%
1 month
16.08%
1 year
41.97%
YTD
36.16%
QTD
11.89%
Financial performance
How have Lumos Pharma's revenue and profit performed over time
Revenue
$2.21M
Gross profit
$2.21M
Operating income
-$36.33M
Net income
-$34.92M
Gross margin
100%
Net margin
-1,583.5%
The revenue has grown by 48% from the previous quarter and by 27% YoY
LUMO's gross profit is up by 48% from the previous quarter and by 27% YoY
LUMO's operating margin is up by 35% QoQ and by 19% YoY
The net margin has grown by 34% since the previous quarter and by 16% year-on-year
Growth
What is Lumos Pharma's growth rate over time
Valuation
What is Lumos Pharma stock price valuation
P/E
N/A
P/B
7.16
P/S
16.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.93
LUMO's EPS is down by 7% year-on-year but it is up by 3.2% since the previous quarter
The P/B is 175% more than the last 4 quarters average of 2.6
The equity has plunged by 86% YoY and by 52% from the previous quarter
The P/S is 97% lower than the 5-year quarterly average of 497.6 but 19% higher than the last 4 quarters average of 13.7
The revenue has grown by 48% from the previous quarter and by 27% YoY
Efficiency
How efficient is Lumos Pharma business performance
LUMO's ROA has dropped by 137% year-on-year and by 25% since the previous quarter
LUMO's ROE is down by 47% QoQ
LUMO's return on sales is up by 34% since the previous quarter and by 16% year-on-year
Dividends
What is LUMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUMO.
Financial health
How did Lumos Pharma financials performed over time
The company's total assets is 39% higher than its total liabilities
LUMO's quick ratio has dropped by 70% year-on-year and by 39% since the previous quarter
The current ratio has dropped by 66% year-on-year and by 37% since the previous quarter
The debt is 96% smaller than the equity
The equity has plunged by 86% YoY and by 52% from the previous quarter
The debt has dropped by 62% since the previous quarter and by 36% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.